Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Pfizer: 3 Key Takeaways for Long-Term Investors

The patent-expiry question is still open: whether cutting costs now buys enough time for late-stage trials to replace fading blockbuster revenue.

We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at fool.com →

More in Finance & Markets

More from Wednesday 4 November →